Kristin E Schneider1, Allison O'Rourke2, Rebecca Hamilton White3, Ju Nyeong Park4, Raschelle J Musci5, Michael E Kilkenny6, Susan G Sherman7, Sean T Allen8. 1. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, 624N. Broadway, HH886, Baltimore, MD 21205, USA. Electronic address: kschne18@jhu.edu. 2. DC Center for AIDS Research, Department of Psychology, George Washington University, 2125G St. NW, Washington, DC 20052, USA. Electronic address: orourkea@gwu.edu. 3. Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, 624N. Broadway, Baltimore, MD 21205, USA. Electronic address: rwhite75@jhmi.edu. 4. Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, 624N. Broadway, Baltimore, MD 21205, USA. Electronic address: ju.park@jhu.edu. 5. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, 624N. Broadway, HH886, Baltimore, MD 21205, USA. Electronic address: rmusci1@jhu.edu. 6. Cabell-Huntington Health Department, 703 7th Ave, Huntington, WV 25701, USA. Electronic address: Michael.E.Kilkenny@wv.gov. 7. Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, 624N. Broadway, Baltimore, MD 21205, USA. Electronic address: ssherman@jhsph.edu. 8. Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, 624N. Broadway, Baltimore, MD 21205, USA. Electronic address: sallen63@jhu.edu.
Abstract
BACKGROUND: Rural communities in the United States have been disproportionately affected by the opioid crisis. Little research has explored the relationship between polysubstance use and overdose experiences among people who inject drugs (PWID) in rural communities. We sought to identify classes of polysubstance drug use among rural PWID and evaluate the associations between polysubstance drug use classes, recent overdose experiences, and receipt of take-home naloxone (THN). METHODS: We surveyed 420 PWID (June-July 2018) who had injected drugs in the previous 6 months in Cabell County, West Virginia. Participants were recruited from the local syringe services program and through street-based recruitment. We conducted a latent class analysis using 9 measures of injection and non-injection drug use and tested for associations with having experienced an overdose in the past 6 months and having received THN in the past 6 months. RESULTS: We identified four substance use classes in our sample: polydrug/polyroute use (35.0% of the sample), polyroute stimulant/injection opioid use (33.3%), polyroute stimulant use (20.3%), and injection opioid use (11.3%). Overall, 42.6% of the sample had experienced an overdose in the past 6 months. The classes differed in terms of overdose (χ=91.53, p<0.001), with the polydrug/polyroute use class having the highest probability of overdose and the polyroute stimulants class having the lowest. Only 46.5% of participants had received THN, and probabilities differed between classes (χ=21.93, p<0.001). The polyroute stimulants/injection opioid use and polydrug/polyroute use classes had the highest levels of THN receipt while the polyroute stimulants use class had the least. CONCLUSION: Among rural PWID in West Virginia, polysubstance use was prevalent and associated with overdose and THN acquisition. These analyses demonstrate the importance of scaling up naloxone distribution in rural settings. Overdose prevention initiatives are reaching persons at high risk of overdose, but expansion of services is needed.
BACKGROUND: Rural communities in the United States have been disproportionately affected by the opioid crisis. Little research has explored the relationship between polysubstance use and overdose experiences among people who inject drugs (PWID) in rural communities. We sought to identify classes of polysubstance drug use among rural PWID and evaluate the associations between polysubstance drug use classes, recent overdose experiences, and receipt of take-home naloxone (THN). METHODS: We surveyed 420 PWID (June-July 2018) who had injected drugs in the previous 6 months in Cabell County, West Virginia. Participants were recruited from the local syringe services program and through street-based recruitment. We conducted a latent class analysis using 9 measures of injection and non-injection drug use and tested for associations with having experienced an overdose in the past 6 months and having received THN in the past 6 months. RESULTS: We identified four substance use classes in our sample: polydrug/polyroute use (35.0% of the sample), polyroute stimulant/injection opioid use (33.3%), polyroute stimulant use (20.3%), and injection opioid use (11.3%). Overall, 42.6% of the sample had experienced an overdose in the past 6 months. The classes differed in terms of overdose (χ=91.53, p<0.001), with the polydrug/polyroute use class having the highest probability of overdose and the polyroute stimulants class having the lowest. Only 46.5% of participants had received THN, and probabilities differed between classes (χ=21.93, p<0.001). The polyroute stimulants/injection opioid use and polydrug/polyroute use classes had the highest levels of THN receipt while the polyroute stimulants use class had the least. CONCLUSION: Among rural PWID in West Virginia, polysubstance use was prevalent and associated with overdose and THN acquisition. These analyses demonstrate the importance of scaling up naloxone distribution in rural settings. Overdose prevention initiatives are reaching persons at high risk of overdose, but expansion of services is needed.
Authors: Karen Shiu-Yee; Ahnalee M Brincks; Daniel J Feaster; Jemima A Frimpong; Ank Nijhawan; Raul N Mandler; Robert Schwartz; Carlos Del Rio; Lisa R Metsch Journal: AIDS Behav Date: 2018-09
Authors: Andrew Kolodny; David T Courtwright; Catherine S Hwang; Peter Kreiner; John L Eadie; Thomas W Clark; G Caleb Alexander Journal: Annu Rev Public Health Date: 2015-01-12 Impact factor: 21.981
Authors: William T Robinson; Catherine Kazbour; Tanner Nassau; Kiva Fisher; Shane Sheu; Alexis V Rivera; Alia Al-Tayyib; Sara Nelson Glick; Sarah Braunstein; Narquis Barak; Jennifer Shinefeld; Jonathon Poe; Henry Fisher Raymond; Kathleen Brady Journal: J Acquir Immune Defic Syndr Date: 2017-07-01 Impact factor: 3.731
Authors: Jon E Zibbell; Alice K Asher; Rajiv C Patel; Ben Kupronis; Kashif Iqbal; John W Ward; Deborah Holtzman Journal: Am J Public Health Date: 2017-12-21 Impact factor: 9.308
Authors: Meredith C Meacham; Abby E Rudolph; Steffanie A Strathdee; Melanie L Rusch; Kimberly C Brouwer; Thomas L Patterson; Alicia Vera; Gudelia Rangel; Scott C Roesch Journal: Subst Use Misuse Date: 2015-10-07 Impact factor: 2.164
Authors: Tarlise Townsend; David Kline; Ariadne Rivera-Aguirre; Amanda M Bunting; Pia M Mauro; Brandon D L Marshall; Silvia S Martins; Magdalena Cerdá Journal: Am J Epidemiol Date: 2022-03-24 Impact factor: 5.363
Authors: Mari-Lynn Drainoni; Hannah K Knudsen; Kathy Adams; Shaquita A Andrews-Higgins; Vanessa Auritt; Sandi Back; Laura K Barkowski; Evan J Batty; Melika R Behrooz; Sydney Bell; Sadie Chen; Mia-Cara Christopher; Nicolette Coovert; Erika L Crable; Anindita Dasgupta; Michael Goetz; Dawn Goddard-Eckrich; Jeanie L Hartman; Holly Heffer; Pulwasha Iftikhar; Latasha Jones; Samantha Lang; Karsten Lunze; Anna Martin; Tara McCrimmon; Melissa K Reedy-Johnson; Carter Roeber; Ariel L Scalise; Cynthia J Sieck; Daniel M Walker; Galya Walt; Jennifer D Wood; Priscilla Zito; Ann Scheck McAlearney Journal: J Subst Abuse Treat Date: 2022-01-31
Authors: Tyler S Bartholomew; Hansel E Tookes; Corinne Bullock; Jason Onugha; David W Forrest; Daniel J Feaster Journal: Int J Drug Policy Date: 2020-03-05
Authors: James J Mahoney; Erin L Winstanley; Laura R Lander; James H Berry; Patrick J Marshalek; Marc W Haut; Jennifer L Marton; Wesley D Kimble; Matthew Armistead; Sijin Wen; Yilin Cai; Sally L Hodder Journal: Addict Behav Date: 2020-12-04 Impact factor: 3.913
Authors: Andrea M Lopez; Zena Dhatt; Mary Howe; Marwa Al-Nassir; Amy Billing; Eleanor Artigiani; Eric D Wish Journal: Int J Drug Policy Date: 2021-01-19
Authors: Kristin E Schneider; Rebecca Hamilton White; Allison O'Rourke; Michael E Kilkenny; Michelle Perdue; Susan G Sherman; Suzanne M Grieb; Sean T Allen Journal: AIDS Care Date: 2020-09-21
Authors: Rebecca Hamilton White; Allison O'Rourke; Michael E Kilkenny; Kristin E Schneider; Brian W Weir; Suzanne M Grieb; Susan G Sherman; Sean T Allen Journal: Addiction Date: 2020-07-14 Impact factor: 6.526